CD19 and B-cell chronic lymphocytic leukemia: In March 2024, the CD19‐directed CAR T‐cell therapy lisocabtagene maraleucel (liso‐cel) received accelerated approval for the treatment of R/R CLL following ≥ 2 lines of therapy including a BTKi and BCL2i.